Please assess the completion status of the following clinical trial:

Trial Title: Imuran Dosing in Crohn's Disease Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 10-70 years-old., Weigh 20-100 kg (44-220 lbs).~* CD of the ileum, colon or ileocolon, verified by colonoscopy, barium enema, or small bowel series performed within 36 months~* Perianal fistulae will be eligible provided that the perianal disease does not account for the preponderance of symptoms.~* Have steroid-dependent, steroid-refractory or steroid naive CD.~  * Steroid-dependent CD: CDAI or mCDAI of \< 150 while receiving prednisone 10-40 mg/day or budesonide 3-9 mg/day for at least 12 weeks prior to screening, but unable to taper prednisone below 10 mg/day or budesonide below 3 mg/day without experiencing a flare within the previous 6 months. Steroids must be at a stable dose for 2 weeks prior to screening (week #-2), prednisone at a dose of 10-40 mg/day and budesonide at a dose of 3-9 mg/day.~ * Steroid-refractory CD: currently moderately active CD (CDAI or mCDAI 200 - 450) despite treatment with 40 kg) or 0.5 mg/kg/day (if weighing 20 mg/day (if weighing prednisone \<40 9 mg/day for the previous 4 weeks prior to the screening kg), or budesonide evaluation. Prednisone or budesonide must be at a stable dose for 2 weeks prior to screening (week #-2).~ * Steroid-naïve CD: currently moderately active CD, (CDAI or mCDAI 200 - 450) and one of the following:~    1. Despite treatment with aminosalicylates and/or antibiotics for the previous 4 weeks prior to the screening evaluation, who are candidates for prednisone or budesonide.~   2. Not currently on therapy, who are candidates for prednisone or budesonide~   3. Patients with prior exposure to steroids, who have not been treated with steroids for 4 weeks prior to screening, and are candidates for prednisone or budesonide Prednisone or budesonide will be started at the screening visit, at a dose of 40 mg/day or 9 mg/day and tapered per the steroid taper.~Patients who have started steroids up to 14 days prior to screening will also qualify as steroid naïve, however patient needs to be on 40 mg prednisone or 9 mg budesonide.~* Discontinue oral or rectal 5-Aminosalicylic acid (5-ASA) therapies, rectal steroids, ciprofloxacin or metronidazole at the screening visit.~Exclusion Criteria:~* CDAI \> 450~* CD requiring hospitalization and intravenous (iv) corticosteroids, iv antibiotics or total parenteral nutrition (TPN).~* TPN or enteral nutrition of \>1000 Calories/day (both TPN and elemental diets impact the CDAI).~* History of resection of more than 100 cm of small bowel, total proctocolectomy, or subtotal colectomy with ileorectal anastomosis~* Ileostomy or colostomy~* Severe fixed symptomatic stenosis of the small or large intestine~* Blood transfusion within 3 months before screening~* Treatment with 6-MP or AZA within the 6 months prior to screening~* Immunosuppressants or biologics 3 months before screening~* Treatment 2 weeks before screening:~  * Allopurinol;~ * Trimethoprim-sulfamethoxazole;~ * NSAIDs or aspirin \>81mg/day;~ * Cholestyramine or other drugs interfering with enterohepatic circulation;~ * Furosemide and thiazide diuretics;~ * Fish-oil preparations.~* Discontinue use at screening: Oral or rectal 5-ASA, rectal steroids, metronidazole or quinolones~* Any prior treatment with natalizumab~* Presence of abnormal laboratory parameters:~* Carriage of hepatitis B surface antigen or positive hepatitis C antibody~* Lack of one acceptable form of contraception while receiving AZA~* Low TPMT activity

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Azathioprine weight-based dose (Type: ACTIVE_COMPARATOR): None
- Azathioprine individualised dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).